Zhao Z Q, Nakanishi K, McGee D S, Tan P, Vinten-Johansen J
Department of Cardiothoracic Surgery, Bowman Gray School of Medicine, Winston-Salem, NC 27157.
Cardiovasc Res. 1994 Feb;28(2):270-9. doi: 10.1093/cvr/28.2.270.
The aim was to test the hypothesis that A1 receptor mediated cardioprotection by endogenous adenosine is exerted during ischaemia rather than reperfusion.
Anaesthetised open chest rabbits were subjected to 30 min regional ischaemia and 120 min reperfusion, and randomised to one of six groups: group I--saline vehicle (VEH) (n = 12) to allow A1 and A2 adenosine receptor interactions during ischaemia and reperfusion; group II--both A1 and A2 receptors were antagonised during ischaemia and reperfusion with 8-p-sulphophenyltheophylline (SPT) (10 mg.kg-1) (SPTIR, n = 14); groups III and IV--the selective A1 adenosine receptor antagonist 8-(3-noradamantyl)-1,3-dipropylxanthine (KW-3902) was given during ischaemia-reperfusion in low dose (1 mg.kg-1, LA1-IR, n = 11) and higher dose (2 mg.kg-1, HA1-IR, n = 6); group V--KW-3902 (1 mg.kg-1) was given only during reperfusion (A1-R, n = 12); group VI--SPT was given only at reperfusion (SPTR, n = 11).
In in vitro studies, (1) KW-3902 completely inhibited negative inotropic effects of the A1 agonist R(-)N6-(2-phenylisopropyl) adenosine (R-PIA) in catecholamine stimulated papillary muscles, and (2) had no effect on concentration dependent vasorelaxation to adenosine or R-PIA. In in vivo studies, transmural myocardial blood flow in the area at risk (determined using 15 microns radiolabelled microspheres) was reduced by 98% in all groups from 139(SEM 15.8) to 2.7(1.1) ml.min-1 x 100 g-1 (p < 0.001). At 120 min of reperfusion, blood flow in the area of necrosis was significantly less in groups LA1-IR [48.6(6.2)], HA1-IR [36.1(7.1)], SPTIR [35.9(6.4)], and SPTR [25.1(5.4)] compared to groups VEH [69.1(15.8)] and A1-R [77.2(11.8)]. The area at risk (Ar) was equivalent among groups. SPT treatment during ischaemia-reperfusion in the SPTIR group increased the area of necrosis (An, assessed by triphenyltetrazolium chloride) relative to Ar (An/Ar) to 51(1.9)% v 26.0(1.7)% in VEH group. KW-3902 in LA1-IR and HA1-IR during both ischaemia and reperfusion increased An/Ar to 35.2(2.5)% and 35.2(2.1)% of area at risk, respectively, both of which were significantly less than the SPTIR group. With A1 blockade at reperfusion (A1-R), An/Ar was equivalent to that in VEH [27.0(1.9)%], while an infarct size of 46.7(2.1)% was still observed in SPTR.
While adenosine exerts its predominant modulation of infarct size during reperfusion, the cardioprotection mediated by A1 receptor mechanisms is modest and exerted principally during the ischaemic time period.
旨在验证内源性腺苷通过A1受体介导的心脏保护作用是在缺血期而非再灌注期发挥的这一假说。
对麻醉开胸兔进行30分钟局部缺血和120分钟再灌注,并随机分为六组:第一组——生理盐水载体(VEH)(n = 12),以允许在缺血和再灌注期间A1和A2腺苷受体相互作用;第二组——在缺血和再灌注期间用8 - 对 - 磺基苯基茶碱(SPT)(10 mg·kg-1)拮抗A1和A2受体(SPTIR,n = 14);第三组和第四组——在缺血 - 再灌注期间给予低剂量(1 mg·kg-1,LA1 - IR,n = 11)和高剂量(2 mg·kg-1,HA1 - IR,n = 6)的选择性A1腺苷受体拮抗剂8 -(3 - 去甲金刚烷基)-1,3 - 二丙基黄嘌呤(KW - 3902);第五组——仅在再灌注期间给予KW - 3902(1 mg·kg-1)(A1 - R,n = 12);第六组——仅在再灌注时给予SPT(SPTR,n = 11)。
在体外研究中,(1)KW - 3902完全抑制了A1激动剂R(-)N6 -(2 - 苯异丙基)腺苷(R - PIA)在儿茶酚胺刺激的乳头肌中的负性肌力作用,且(2)对腺苷或R - PIA的浓度依赖性血管舒张无影响。在体内研究中,所有组中危险区域的透壁心肌血流量(使用15微米放射性标记微球测定)从139(标准误15.8)降至2.7(1.1)ml·min-1×100 g-1,降低了98%(p < 0.001)。在再灌注120分钟时,与VEH组[69.1(15.8)]和A1 - R组[77.2(11.8)]相比,LA1 - IR组[48.6(6.2)]、HA1 - IR组[36.1(7.1)]、SPTIR组[35.9(6.4)]和SPTR组[25.1(5.4)]中坏死区域的血流量明显减少。各组间危险区域(Ar)相当。SPTIR组在缺血 - 再灌注期间进行SPT治疗使坏死面积(通过氯化三苯基四氮唑评估)相对于Ar(An/Ar)增加至51(1.9)%,而VEH组为26.0(1.7)%。在缺血和再灌注期间,LA1 - IR组和HA1 - IR组中的KW - 3902分别使An/Ar增加至危险区域的35.2(2.5)%和35.2(2.1)%,两者均显著低于SPTIR组。在再灌注时进行A1阻断(A1 - R),An/Ar与VEH组相当[27.0(1.9)%],而在SPTR组中仍观察到梗死面积为46.7(2.1)%。
虽然腺苷在再灌注期间对梗死面积起主要调节作用,但A1受体机制介导的心脏保护作用较小且主要在缺血期发挥。